29 slides from Imagion Biosystems's shareholder meeting presentation, May 25, 2022
Slide 1: A Breakthrough in Magnetic Molecular Imaging – AGM Investor Presentation
For personal use only A Breakthrough in Magnetic Molecular Imaging AGM Investor Presentation 25 May 2022 Imagion Biosystems Limited ImagionBiosystems.com ASX:IBX
Slide 2: Disclaimers
Disclaimers Imagionbiosystems.com For personal use only This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to s
Slide 3: Investment Highlights
Investment Highlights Imagionbiosystems.com For personal use only $ A Clinical Stage Medical Addressing large MagSense® technology Multiple revenue 3 Strong leadership Device Company markets and unmet will transform cancer opportunities and advisory board developing bio-safe needs in earlier more di
Slide 4: Company Overview
For personal use only 01 Company Overview 4
Slide 5: Imagion Biosystems Overview
Imagion Biosystems Overview Imagionbiosystems.com For personal use only A clinical stage medical device company developing next generation molecular Imagion Biosystems imaging technologies ASX:IBX Market cap: ~$48 million • Innovative medical imaging using bio-safe magnetic nanoparticles to identify
Slide 6: Recent Milestones
Imagion Biosystems Overview Imagionbiosystems.com For personal use only Recent Milestones Jul 2019 Received FDA designation as a ”Breakthrough Device” May 2020 Research collaboration with Siemens Oct 2020 HREC approval for MagSense® HER2 Breast Cancer Phase I study Dec 2020 MagSense® HER2 Breast Can
Slide 7: Medical Imaging Breakthrough
Medical Imaging Breakthrough Imagionbiosystems.com For personal use only MagSense® Technology will transform cancer diagnosis Non-invasive – a safe and non-surgical solution to detect cancer No radioactivity – uses bio-safe magnetic nanoparticles to “tag” cancer cells Specific – use of targeted imag
Slide 8: How It Works
How It Works Imagionbiosystems.com For personal use only Bio-safe magnetic nanoparticles are attracted to the tumor and detected Patients are given a low dose injection of the nanoparticle imaging agent. Targeting antibodies affixed to the nanoparticles, ensure high specificity for the cancer, and c
Slide 9: The MagSense Technology Process
The MagSense Technology Process® Imagionbiosystems.com For personal use only 1 2 3 4 Clinical assessment MagSense® nanoparticle Area scanned for Physician sees “hotspot” identifies need for test. reagent given to patient. magnetic signature. image if tumor present. Works within current standard canc
Slide 10: How It Works - Video
How It Works - Video Imagionbiosystems.com For personal use only Click play to watch video in browser 10
Slide 11: Transformative for Medical Imaging: MagSense HER2 Metastatic Breast Cancer Test
Transformative for Medical Imaging Imagionbiosystems.com For personal use only The MagSense® HER2 Metastatic Breast Cancer Test • Works within current standard cancer diagnosis and staging protocols The MagSense® HER2 • Replaces current non-functional imaging such as MRI or ultrasound used to assess
Slide 12: A Global Medical Need
For personal use only 02 A Global Medical Need $100 billion spent annually to diagnose or Each year cancer kills 9 million people detect cancer, yet cancer continues to be a leading cause of mortality and morbidity.
Slide 13: A Growing Global Health Problem
A Growing Global Health Problem Imagionbiosystems.com For personal use only 1 in 3 people are affected by cancer US$100 BILLION CANCER DIAGNOSTICS MARKET $30,000 $26.0b $25,000 $20.1b $20,000 Millions (USD) $15.5b $15,000 $9.6b $10,000 $8.9b $7.2b $5.9b $3.1b $4.6b $5,000 $- * Source: Transparency M
Slide 14: Clear Unmet Medical Need
Clear Unmet Medical Need Imagionbiosystems.com For personal use only Anatomical images can’t differentiate benign from malignant lesions X-RAY COMPUTED TOMOGRAPHY POSITRON EMISSION ULTRASOUND MAGNETIC RESONANCE (MRI) (MAMMOGRAPHY) (CT) TOMOGRAPHY (PET) Mammography used for Inexpensive but poor Able
Slide 15: Improving Outcomes
Improving Outcomes Imagionbiosystems.com For personal use only MagSense® technology is expected to have sensitivity comparable to PET without use of radioactivity, making it better for routine use in early detection and resulting in more successful treatments and patient outcomes. Better sensitivity
Slide 16: Broad Commercial Applicability
Broad Commercial Applicability Imagionbiosystems.com For personal use only MagSense® imaging agents can be 1 Brain Cancer developed for many types of solid 2 Breast Cancer tumors and can be used at multiple stages of diagnosis including primary 3 Lung Cancer diagnosis, staging, and monitoring 4 Ovar
Slide 17: Pre-Clinical Research
Pre-Clinical Research Imagionbiosystems.com For personal use only Proof-of-principle verified in pre-clinical models Specificity • In vitro cell based studies confirm specificity for targeting the specific cancer cells. • Animal studies confirm in vivo selectivity for ”tagging” the tumour. Sensitivi
Slide 18: Clinical Trial
Clinical Trial Imagionbiosystems.com For personal use only Phase 1 Study for Nodal Staging of HER2 Metastatic Breast Cancer • Multi-site study for patients with HER2 positive primary tumor • Interim results (first five patients) show no safety or Phase I Study Multi-Site in AUS Timing tolerability i
Slide 19: Growth Strategy
For personal use only 03 Growth Strategy 19
Slide 20: Compelling Business Model
Compelling Business Model Imagionbiosystems.com For personal use only Proprietary Consumables Drive Growth & Profitability Lower Cost Capital Does not require Licensing or Commercial Imagion receives Sale than MRI or CT ~ installation expense Partnership with Medical licensing/milestone fees $500K U
Slide 21: Nanoparticles Are at the Core of Our Business Model
Nanoparticles Are at the Core of Our Business Model Imagionbiosystems.com For personal use only Research OEM Diagnostic Sales Sales Imaging • Direct sales of PrecisionMRX® • Revenue generated from • Revenue generated from nanoparticles to institutions contract research fees. strategic partners in th
Slide 22: Business Strategy
Business Strategy For personal use only Use MagSense® HER2 Expand the pipeline Collaborate in other Create a high-value Test as a commercial biomedical applications biomedical portfolio launchpad Build a pipeline of other diagnostic imaging agents Generate revenue through Align with strategic partne
Slide 23: Leadership and Financials
For personal use only 04 Leadership and Financials 23
Slide 24: Experienced Board and Management
Experienced Board and Management Imagionbiosystems.com Commercially focused team with deep industry & clinical experience For personal use only ROBERT PROULX YALIA JAYALAKSHMI MICHAEL HARSH DAVID LUDVIGSON DIANNE ANGUS CHAIRMAN & CEO CHIEF DEVELOPMENT OFFICER NON-EXEC DIRECTOR NON-EXEC DIRECTOR NON-
Slide 25: Scientific Advisory Board
Scientific Advisory Board Imagionbiosystems.com For personal use only Collective expertise in oncology, medical imaging, nanotechnology, clinical trial design DR JOHN HAZLE PROF LISA HORVARTH DR ROBERT IVKOV SCIENTIFIC ADVISORY BOARD CHAIR • Director, Department of Medical Oncology, • Expertise in r
Slide 26: Collaborators and Partners
Collaborators and Partners Imagionbiosystems.com For personal use only MD Anderson Cancer Center World class scientific o In 2015 the MD Anderson established a Magnetic Relaxometry Research Laboratory to help validate the Imagion technology for various cancer targets. collaborations & partnerships:
Slide 27: Capital and Financial Snapshot
Capital and Financial Snapshot Imagionbiosystems.com For personal use only Ordinary shares on issue 1,121 million Imagion ended Q12022 with $10.6 million Listed and unlisted options 284 million • 2021 cash flows were funded by cash Share price (23 May 2022) $0.043 reserves, exercise of listed option
Slide 28: Historical Cash Flows
Historical Cash Flows Imagionbiosystems.com For personal use only 2020 2021 2022 Operating Q1 AUD '000 Q2 AUD '000 Q3 AUD '000 Q4 AUD '000 Q1 AUD '000 Q2 AUD '000 Q3 AUD '000 Q4 AUD '000 Q1 AUD’000 Receipts from customers 50 26 82 65 41 48 34 84 95 Payments - R&D (492) (1,036) (794) (790) (490) (645
Slide 29: For personal use only
For personal use only www.imagionbiosystems.com info@imagionbio.com ASX:IBX